Navigation Links
Risk assessment tool not reliable predictor for some women at high risk of breast cancer
Date:11/5/2008

ROCHESTER, Minn. -- A statistical model commonly used to predict the risk of breast cancer in women was not accurate when used to evaluate women with atypical hyperplasia, according to a new Mayo Clinic study published in the Oct. 14, 2008, issue of the Journal of Clinical Oncology. Atypical hyperplasia (atypia) describes breast tissue with an increased growth of abnormal cells that might become cancerous.

The Gail model calculates probabilities that a woman will develop invasive breast cancer during the next five years, and by age 90. The model has come to be called by the name of its developer, National Cancer Institute researcher Mitchell Gail, M.D., Ph.D. Its original purpose was to identify groups of high-risk women for participation in breast cancer chemoprevention studies. But the model has since been used in clinical settings to counsel individuals about their risk of developing breast cancer. Predicting risk at an individual level is much more challenging than when risks can be averaged across groups.

"The assumption has always been that this model works well in women with atypia, but this had never been validated," says Shane Pankratz, Ph.D., Mayo Clinic statistician and a lead investigator in the study. "We found that, for the group of women with atypia, the model predicted significantly fewer invasive breast cancers than were actually observed, and we also observed that the model was not able to reliably identify the women who were actually at higher risk of developing breast cancer."

The Gail model considers the woman's family history of breast cancer, her age, and her ages at the onset of menstruation and at first live birth, as well as the number of breast biopsies undergone and presence of atypical hyperplasia found in biopsies. About 5 percent of women who undergo biopsies for suspicious lumps or other breast concerns have atypia. About 25 percent of those with atypia will develop cancer within 25 years.

Mayo Clinic researchers tested the Gail model in 331 women with atypia who had benign breast biopsies at Mayo Clinic between 1967 and 1991. Of these women, 58 developed cancer during an average of 13.7 years of follow-up. In contrast, the model predicted that 34.9 women would develop breast cancer in that period.

Using these and other data, researchers also calculated the model's performance for individuals using the concordance statistic (c-statistic), which reflects how closely the actual timing of breast cancer events aligned with model predictions. A c-statistic of 0.5 is observed if the predictions are no better than random chance; a c-statistic of 1.0 is observed if the predictions are perfectly concordant with the actual outcomes. In this study, the c-statistic was 0.5, reflecting that the Gail model worked no better than a coin flip in predicting which of the women with atypia would develop invasive breast cancer.

When assessed across other groups of women without respect to the presence of atypia, the Gail model typically performs better. In that setting, it has been shown to predict approximately the same number of breast cancers that later occur.

Lynn Hartmann, M.D., Mayo Clinic oncologist and co-investigator on the study, says that there is strong interest in predicting breast cancer risk. For example, the Gail model, posted on the National Cancer Institute's Web site (http://www.cancer.gov/bcrisktool/), attracts 25,000 viewers each month.

"Doctors counsel women at high risk to have more frequent or intensive surveillance or to consider chemoprevention strategies such as tamoxifen or raloxifene," says Dr. Hartmann. "When making such decisions, women and their physicians must have highly reliable risk estimates."

Researchers are pursuing other avenues to better predict individual risk. Previously, Mayo Clinic researchers found that women with multiple sites of cellular atypia in a breast biopsy have significantly increased risk of developing breast cancer. In a study published earlier this year, Mayo researchers found that women whose atypia tissues express COX-2 enzymes were more likely to develop breast cancer, and the higher the COX-2 levels, the higher the risk.


'/>"/>

Contact: Karl Oestreich
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
2. Personality can hamper a physicians assessment of depression
3. Simple, inexpensive and objective tools for the assessment of mucosal inflammation: fecal markers
4. California Dental Association Foundation Launches New Dental Risk Assessment Campaign
5. Notice of Proposed Rulemaking on U.S. Department of Labors Risk Assessment Procedures Published in Federal Register
6. DIA Conference to Provide New Paradigms in Evidence-Based Medicine and Health Technology Assessment
7. Risk assessment plays key role in long-term treatment of breast cancer
8. InfoLogix Launches Strategic Mobility Assessment Service for Hospitals
9. The Supports Intensity Scale Assessment Can be Used to Build Robust Funding Methods for Developmental Disability Services, New Research Reveals
10. Fox Learning Systems Selects Prymaks Discovery-180(TM) Technology Assessment to Guide Search for New LMS
11. Combined Insurance Provides Needs Assessment Checklist to Help Consumers Evaluate Their Current Supplemental Health Insurance Coverage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
Breaking Medicine Technology: